Updating results

386 results

Sort: Relevance | Date

Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer (TA563)

Evidence-based recommendations on abemaciclib (Verzenios) for treating locally advanced or metastatic, hormone receptor-positive, human epidermal growth factor

Technology appraisal guidance Published February 2019

Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma (TA562)

Evidence-based recommendations on encorafenib (Braftovi) with binimetinib (Mektovi) for treating unresectable or metastatic BRAF V600 mutation-positive melanoma

Technology appraisal guidance Published February 2019

Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia (TA561)

Evidence-based recommendations on venetoclax (Venclyxto) with rituximab for previously treated chronic lymphocytic leukaemia in adults

Technology appraisal guidance Published February 2019

Bevacizumab with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer (terminated appraisal) (TA560)

NICE is unable to make a recommendation about the use in the NHS of bevacizumab with carboplatin, gemcitabine and paclitaxel for treating the first recurrence

Technology appraisal guidance Published February 2019

Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema in phakic eyes after an inadequate response to previous therapy (TA613)

Evidence-based recommendations on fluocinolone acetonide intravitreal implant (Iluvien) for chronic diabetic macular oedema that has inadequately responded to

Technology appraisal guidance Published November 2019

Cenegermin for treating neurotrophic keratitis (TA532)

Evidence-based recommendations on cenegermin (Oxervate) for treating neurotrophic keratitis in adults

Technology appraisal guidance Published July 2018

Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer (TA531)

Evidence-based recommendations on pembrolizumab (Keytruda) for untreated PD-L1-positive metastatic non-small-cell lung cancer (NSCLC) in adults

Technology appraisal guidance Published July 2018

Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA537)

Evidence-based recommendations on ixekizumab (Taltz) for treating active psoriatic arthritis after inadequate response to DMARDs in adults

Technology appraisal guidance Published August 2018

Alectinib for untreated ALK-positive advanced non-small-cell lung cancer (TA536)

Evidence-based recommendations on alectinib (Alecensa) for untreated anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer in adults

Technology appraisal guidance Published August 2018

Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine (TA535)

Evidence-based recommendations on lenvatinib (Lenvima) and sorafenib (Nexavar) for differentiated thyroid cancer in adults who have had radioactive iodine

Technology appraisal guidance Published August 2018

Dupilumab for treating moderate to severe atopic dermatitis (TA534)

Evidence-based recommendations on dupilumab (Dupixent) for treating moderate to severe atopic dermatitis in adults

Technology appraisal guidance Published August 2018

Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma (TA540)

Evidence-based recommendations on pembrolizumab (Keytruda) for treating relapsed or refractory classical Hodgkin lymphoma (cHL) in adults

Technology appraisal guidance Published September 2018

Lenvatinib for untreated advanced hepatocellular carcinoma (TA551)

Evidence-based recommendations on lenvatinib (Lenvima) for untreated advanced hepatocellular carcinoma (HCC) in adults

Technology appraisal guidance Published December 2018

Gemtuzumab ozogamicin for untreated acute myeloid leukaemia (TA545)

Evidence-based recommendations on emtuzumab oxogamicin (Mylotarg) for untreated acute myeloid leukaemia (AML) in people aged 15 years and over

Technology appraisal guidance Published November 2018

Vandetanib for treating medullary thyroid cancer (TA550)

Evidence-based recommendations on vandetanib (Caprelsa) for treating medullary thyroid cancer in adults

Technology appraisal guidance Published December 2018

Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy (TA490)

Evidence-based recommendations on nivolumab (Opdivo) for squamous cell carcinoma (SCC) of the head and neck in adults who have had platinum-based chemotherapy

Technology appraisal guidance Published November 2017

Vismodegib for treating basal cell carcinoma (TA489)

Evidence-based recommendations on vismodegib (Erivedge) for treating basal cell carcinoma (BCC; non-melanoma skin cancer; rodent ulcers) in adults

Technology appraisal guidance Published November 2017

Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours (TA488)

Evidence-based recommendations on on regorafenib (Stivarga) for previously treated gastrointestinal stromal tumours in adults

Technology appraisal guidance Published November 2017

Naltrexone–bupropion for managing overweight and obesity (TA494)

Evidence-based recommendations on naltrexone–bupropion (Mysimba) for managing overweight and obesity in adults

Technology appraisal guidance Published December 2017

Cladribine tablets for treating relapsing–remitting multiple sclerosis (TA493)

Evidence-based recommendations on cladribine tablets (Mavenclad) for highly active relapsing–remitting multiple sclerosis (MS) in adults

Technology appraisal guidance Published December 2017

Atezolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (TA492)

Evidence-based recommendations on atezolizumab (Tecentriq) for untreated PD-L1-positive locally advanced or metastatic urothelial carcinoma in adults

Technology appraisal guidance Published December 2017 Last updated July 2018

Venetoclax for treating chronic lymphocytic leukaemia (TA487)

Evidence-based recommendations on venetoclax (Venclyxto) for treating chronic lymphocytic leukaemia in adults

Technology appraisal guidance Published November 2017

Ibrutinib for treating Waldenstrom's macroglobulinaemia (TA491)

Evidence-based recommendations on ibrutinib (Imbruvica) for treating Waldenstrom's macroglobulinaemia (non-Hodgkin lymphoma) in adults after at least 1 therapy

Technology appraisal guidance Published November 2017

Ceritinib for untreated ALK-positive non-small-cell lung cancer (TA500)

Evidence-based recommendations on ceritinib (Zykadia) for untreated anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer (NSCLC)

Technology appraisal guidance Published January 2018

Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer (TA495)

Evidence-based recommendations on palbociclib (Ibrance) as initial endocrine-based therapy for hormone receptor-positive, HER2-negative, locally advanced or

Technology appraisal guidance Published December 2017

Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer (TA496)

Evidence-based recommendations on ribociclib (Kisqali) as initial endocrine-based therapy for hormone-receptor positive, human epidermal growth factor receptor

Technology appraisal guidance Published December 2017

Golimumab for treating non-radiographic axial spondyloarthritis (TA497)

Evidence-based recommendations on golimumab (Simponi) for severe non-radiographic axial spondyloarthritis in adults

Technology appraisal guidance Published January 2018

Cabozantinib for treating medullary thyroid cancer (TA516)

Evidence-based recommendations on cabozantinib (Cometriq) for treating medullary thyroid cancer (MTC) in adults

Technology appraisal guidance Published March 2018

Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab (TA472)

Evidence-based recommendations on obinutuzumab (Gazyvaro) with bendamustine for adults with follicular lymphoma unresponsive to treatment with rituximab

Technology appraisal guidance Published August 2017

Eluxadoline for treating irritable bowel syndrome with diarrhoea (TA471)

Evidence-based recommendations on eluxadoline (Truberzi) for treating irritable bowel syndrome (IBS) with diarrhoea in adults

Technology appraisal guidance Published August 2017

Idelalisib with ofatumumab for treating chronic lymphocytic leukaemia (terminated appraisal) (TA469)

NICE is unable to make a recommendation about the use in the NHS of idelalisib with ofatumumab for treating chronic lymphocytic leukaemia because no evidence

Technology appraisal guidance Published August 2017

Methylnaltrexone bromide for treating opioid-induced constipation (terminated appraisal) (TA468)

NICE was unable to make a recommendation about the use in the NHS of methylnaltrexone bromide for treating opioid-induced constipation because no evidence was

Technology appraisal guidance Published August 2017

Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer (TA476)

Evidence-based recommendations on paclitaxel as albumin-bound nanoparticles (nab-paclitaxel) for untreated metastatic pancreatic cancer in adults

Technology appraisal guidance Published September 2017

Dimethyl fumarate for treating moderate to severe plaque psoriasis (TA475)

Evidence-based recommendations on dimethyl fumarate (Skilarence) for treating moderate to severe plaque psoriasis in adults

Technology appraisal guidance Published September 2017

Sorafenib for treating advanced hepatocellular carcinoma (TA474)

Evidence-based recommendations on sorafenib (Nexavar) for treating advanced hepatocellular carcinoma (liver cancer) in adults

Technology appraisal guidance Published September 2017

Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck (TA473)

Evidence-based recommendations on cetuximab (Erbitux) for treating recurrent or metastatic squamous cell cancer of the head and neck in adults

Technology appraisal guidance Published August 2017

Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab (TA357)

Evidence-based recommendations on pembrolizumab (Keytruda) for treating advanced melanoma after disease progression with ipilimumab in adults

Technology appraisal guidance Published October 2015 Last updated September 2017

Pembrolizumab for advanced melanoma not previously treated with ipilimumab (TA366)

Evidence-based recommendations on pembrolizumab (Keytruda) for treating advanced melanoma in adults not previously treated with ipilimumab

Technology appraisal guidance Published November 2015 Last updated September 2017

Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality (TA322)

Evidence-based recommendations on lenalidomide (Revlimid) for myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality

Technology appraisal guidance Published September 2014 Last updated June 2019

Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence (TA553)

Evidence-based recommendation on pembrolizumab (Keytruda) for adjuvant treatment of completely resected stage III melanoma with lymph node involvement in adults

Technology appraisal guidance Published December 2018

Tofacitinib for moderately to severely active ulcerative colitis (TA547)

Evidence-based recommendations on tofacitinib (Xeljanz) for previously treated moderately to severely active ulcerative colitis in adults

Technology appraisal guidance Published November 2018

Nivolumab with ipilimumab for untreated advanced renal cell carcinoma (TA581)

Evidence-based recommendations on nivolumab (Opdivo) with ipilimumab (Yervoy) for untreated advanced renal cell carcinoma in adults

Technology appraisal guidance Published May 2019

Enzalutamide for hormone-relapsed non-metastatic prostate cancer (TA580)

Evidence-based recommendations on enzalutamide (Xtandi) for treating high-risk hormone-relapsed non-metastatic prostate cancer in adults

Technology appraisal guidance Published May 2019

Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy (TA579)

Evidence-based recommendations on abemaciclib (Verzenios) for treating hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer

Technology appraisal guidance Published May 2019

Ocrelizumab for treating primary progressive multiple sclerosis (TA585)

Evidence-based recommendations on ocrelizumab (Ocrevus) for treating primary progressive multiple sclerosis (MS) in adults

Technology appraisal guidance Published June 2019

Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer (TA584)

Evidence-based recommendations on atezolizumab (Tecentriq) with bevacizumab (Avastin), carboplatin and paclitaxel for metastatic non-squamous NSCLC

Technology appraisal guidance Published June 2019

Nusinersen for treating spinal muscular atrophy (TA588)

Evidence-based recommendations on nusinersen (Spinraza) for treating spinal muscular atrophy in children and adults

Technology appraisal guidance Published July 2019

Lenalidomide plus dexamethasone for previously untreated multiple myeloma (TA587)

Evidence-based recommendations on lenalidomide (Revlimid) plus dexamethasone for previously untreated multiple myeloma in adults

Technology appraisal guidance Published June 2019

Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib (TA586)

Evidence-based recommendations on lenalidomide (Revlimid) plus dexamethasone for multiple myeloma after 1 treatment with bortezomib in adults

Technology appraisal guidance Published June 2019

Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitis (TA590)

Evidence-based recommendations on fluocinolone acetonide intravitreal implant (Iluvien) for treating recurrent non-infectious uveitis in adults

Technology appraisal guidance Published July 2019